Minerva Neurosciences (NERV) Treasury Shares (2025 - 2026)
Minerva Neurosciences' (NERV) quarterly Treasury Shares came in at $3296.0 in Q1 2026, little changed on a QoQ basis from $3296.0 in Q4 2025.
Powered by 
Analysis
Minerva Neurosciences (NERV) Treasury Shares (2025 - 2026) Analysis & Trends
Minerva Neurosciences (NERV) has 9 years of Treasury Shares data on file, last reported at $3296.0 in Q1 2026.
- Quarterly Treasury Shares changed N/A year-over-year to $3296.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3296.0 (changed N/A YoY) and the FY2025 annual result came in at $3296.0, changed N/A from the prior year.
- Treasury Shares was little changed at $3296.0 in Q1 2026, from $3296.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $3296.0 in Q4 2025 to a low of $3296.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 2.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - | 5,539.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5,539.00 |
| Jun 30, 2026 | 5,539.00 |
| Mar 31, 2026 | 3,296.00 |
| Mar 31, 2026 | 3,296.00 |
| Dec 31, 2025 | 3,296.00 |
| Dec 31, 2025 | 3,296.00 |